| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |